User login

Enter your username and password here in order to log in on the website:
Login

Forgot your password?

Please note: While some information will still be current in a year, other information may already be out of date in three months time. If you are in any doubt, please feel free to ask.

Meveol®

Question
Hello

I have just read: « A new treatment against cystic fibrosis could emerge by 2016. This is a project supported by Bpifrance (bank financing and investment) who just released € 10 million for a new medical program called Alipex. Of the three companies involved in research: Alaxia, a Company from Lyon/France. The role of Alaxia in the project will be to develop the component molecules for inhalation therapy. For the moment, all clinical tests have gone very well and clinical trial for humans should be launched by the end of 2014. »
Could you please tell us more regarding this announcement? A drug may it be on the market in just two years? How much credit can you give to this notification? Thank you in advance for your response.
Answer
Hello

Can I invite you to read the press release published in february which gives you more informations regarding this candidat drug, ALX-009 (ou Meveol ®) (www.alaxia-pharma.eu/sites/default/files/pdf/CP%20Alipex%2019-02-2014%20French.pdf).

ALX-009 is presented as « a broad-spectrum antimicrobial agent which showed in vitro and in vivo efficacy on bacterial strains multi-resistant to antibiotics or clumped in biofilms ». It seems to be a molecule which should treat some symptoms of the disease (pulmonary infection) and not the origin of the disease itself.
We have no additional information other than this press release which briefly informs about results of a preclinical step. The clinical trials for patients, mandatory for proving efficacy of the molecule, haven’t begun yet.
We remain vigilant, waiting for a concrete step, in particular, the announcement of the establishment of a clinical trial, in France or abroad.

Best regards,
Anna Ronayette

15.04.2014